Target Name: CD9
NCBI ID: G928
Review Report on CD9 Target / Biomarker Content of Review Report on CD9 Target / Biomarker
CD9
Other Name(s): antigen CD9 | Growth-inhibiting gene 2 protein | 5H9 antigen | Tetraspanin-29 | P24 | CD9 antigen (p24) | GIG2 | tetraspanin-29 | p24 | Motility related protein | p24 antigen | Tspan-29 | 5H9 | CD9 antigen (isoform 1) | MRP-1 | Leukocyte antigen MIC3 | CD9 antigen | motility related protein-1 | BTCC-1 | BA-2/p24 antigen | MIC3 | TSPAN-29 | CD9 variant 1 | DRAP-27 | CD9 molecule | Cell growth-inhibiting gene 2 protein | leukocyte antigen MIC3 | TSPAN29 | Motility-related protein | Antigen defined by monoclonal antibody 602-29 | BA2 | CD9 molecule, transcript variant 1 | cell growth-inhibiting gene 2 protein | CD9_HUMAN

CD9: A Promising Antigen CD9 is a Drug Target and Biomarker

CD9 is a unique human gene that encodes a cell surface protein known as CD9 antigen. CD9 is highly expressed in various tissues and cell types, including blood cells, epithelial cells, and immune cells. It is involved in several physiological processes, including cell adhesion, migration, and signaling. The CD9 antigen has also been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

CD9 as a Drug Target

The potential of CD9 as a drug target is high due to its various functions in the cell. One of the key functions of CD9 is its role in cell adhesion and migration. CD9 is known to be involved in the regulation of cell-cell adhesion by engaging with integrins, which are critical for cell-cell interactions. Several studies have shown that modulating CD9 can be an effective way to control cell behavior, including the regulation of cell migration and the inhibition of cell adhesion.

CD9 has also been shown to play a role in signaling pathways that are important for various cellular processes, including cell proliferation, apoptosis, and inflammation. The CD9 antigen has been shown to interact with several signaling molecules, including TGF-β, NF-kappa-B, and PI3K. These interactions may regulate various cellular processes that are important for human health and disease, including cancer growth and progression.

CD9 as a Biomarker

The potential of CD9 as a biomarker is also high. The CD9 antigen has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and signaling. Several studies have shown that modulating CD9 levels can be an effective way to monitor the effectiveness of treatments for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key advantages of using CD9 as a biomarker is its stability and expression in various tissues and cells. This makes it a promising marker for a variety of applications, including the evaluation of the efficacy of drugs and the diagnosis of diseases. Additionally, the CD9 antigen has been shown to be expressed in a variety of biological samples, including blood, urine, and tissue, which makes it a potential biomarker for a wide range of applications.

CD9 as a Potential therapeutic Target

The potential of CD9 as a therapeutic target is high. The regulation of CD9 by various signaling pathways makes it an attractive target for the development of new drugs. Several studies have shown that modulating CD9 levels can be an effective way to inhibit the growth and progression of cancer cells, including breast cancer and lung cancer.

One of the key advantages of CD9 as a therapeutic target is its involvement in multiple signaling pathways that are important for cellular processes, including cell adhesion, migration, and signaling. This makes it an attractive target for the development of inhibitors that can disrupt these processes and prevent the growth and progression of cancer cells. Additionally, the CD9 antigen has been shown to interact with several signaling molecules, including TGF-β, NF-kappa-B, and PI3K. These interactions may provide insight into the mechanisms of action of potential therapeutic targets for CD9.

Conclusion

In conclusion, CD9 is a unique and promising antigen that has been implicated in a variety of physiological processes. Its role in cell adhesion, migration, and signaling makes it an attractive target for the development of new drugs. Additionally, its stability and expression in various tissues and cells make it a potential biomarker for a wide range of applications. Further research is needed to fully understand the functions of CD9 and its potential as a therapeutic target.

Protein Name: CD9 Molecule

Functions: Integral membrane protein associated with integrins, which regulates different processes, such as sperm-egg fusion, platelet activation and aggregation, and cell adhesion (PubMed:8478605, PubMed:14575715, PubMed:18541721). Present at the cell surface of oocytes and plays a key role in sperm-egg fusion, possibly by organizing multiprotein complexes and the morphology of the membrane required for the fusion (By similarity). In myoblasts, associates with CD81 and PTGFRN and inhibits myotube fusion during muscle regeneration (By similarity). In macrophages, associates with CD81 and beta-1 and beta-2 integrins, and prevents macrophage fusion into multinucleated giant cells specialized in ingesting complement-opsonized large particles (PubMed:12796480). Also prevents the fusion between mononuclear cell progenitors into osteoclasts in charge of bone resorption (By similarity). Acts as a receptor for PSG17 (By similarity). Involved in platelet activation and aggregation (PubMed:18541721). Regulates paranodal junction formation (By similarity). Involved in cell adhesion, cell motility and tumor metastasis (PubMed:8478605, PubMed:7511626)

The "CD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17